MedTrace Logo

A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19

NCT04796402 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 576

Last updated 2021-08-26

No results posted yet for this study

Summary

The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.

Conditions

  • Covid19

Interventions

BIOLOGICAL

Bamlanivimab

700 mg/20mL IV over at least one hour OD

OTHER

Standard of Care

Standard of care includes primary care and specialist care as indicated by the patient's primary care provider

Sponsors & Collaborators

  • Fraser Health Authrority Department of Evaluation and Research Services

    collaborator UNKNOWN

  • Surrey Memorial Hospital Clinical Research Unit

    collaborator UNKNOWN

  • Centre for Health Evaluation and Outcome Sciences

    collaborator UNKNOWN

  • Surrey Hospital Foundation

    collaborator UNKNOWN

  • BC Support Unit

    collaborator OTHER

  • University of British Columbia

    collaborator OTHER

  • Ministry of Health, British Columbia

    collaborator OTHER_GOV

  • Clinical Trials BC (part of the BC Academic Health Science Network)

    collaborator UNKNOWN

  • Fraser Health

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2021-06-07
Completion
2021-12-31
FDA Drug
Yes

Countries

  • Canada

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04796402 on ClinicalTrials.gov